局部晚期远端食管腺癌的诱导治疗:放疗是否总是必要?
基于美国国家癌症数据库2006至2012年接受诱导化疗或诱导放化疗后行食管切除术的4763例cT1-3N1M0或T3N0M0远端食管腺癌患者,诱导放化疗组在T降期、N降期和病理完全缓解率上优于诱导化疗组,但5年生存无差异,多因素分析中诱导放化疗与生存无关。
要点
- 诱导放化疗组T降期39.7% vs 诱导化疗组33.4%(P=0.012),N降期32.0% vs 23.4%(P<0.001)。
- 诱导放化疗组病理完全缓解率13.1% vs 诱导化疗组5.9%(P<0.001)。
- 诱导化疗组切缘阳性率9.6% vs 诱导放化疗组5.5%(P=0.001),但5年生存无显著差异(35.9% vs 37.2%,P=0.33)。
核心结论
- 对于局部晚期远端食管腺癌,诱导放化疗较诱导化疗局部治疗效果更好,但未改善生存,提示放疗可选择性使用。
研究设计与样本
- 回顾性队列研究,纳入美国国家癌症数据库2006至2012年接受诱导化疗或诱导放化疗后行食管切除术的cT1-3N1M0或T3N0M0远端食管腺癌患者4763例。
主要发现
- 诱导放化疗组4323例(90.8%),诱导化疗组440例(9.2%)。
- 两组年龄、性别、种族、Charlson合并症指数、治疗机构类型、临床T或N分期无差异。
- 肿瘤大小≥5 cm是预测使用诱导放化疗的唯一因素(比值比1.46;P=0.006)。
- 诱导放化疗组T降期39.7% vs 诱导化疗组33.4%(P=0.012),N降期32.0% vs 23.4%(P<0.001),病理完全缓解率13.1% vs 5.9%(P<0.001)。
- 诱导化疗组切缘阳性率9.6% vs 诱导放化疗组5.5%(P=0.001)。
临床怎么用
- 作者认为,在此临床情境下放疗可选择性使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare outcomes between induction chemotherapy alone (ICA) and induction chemoradiation (ICR) in patients with locally advanced distal esophageal adenocarcinoma. METHODS: Patients in the National Cancer Database treated with ICA or ICR followed by esophagectomy between 2006 and 2012 for cT1-3N1M0 or T3N0M0 adenocarcinoma of the distal esophagus were compared using logistic regression, Kaplan-Meier analysis, and Cox proportional hazards methods. RESULTS: The study group included 4763 patients, of whom 4323 patients (90.8%) received ICR and 440 patients (9.2%) received ICA. There were no differences in age, sex, race, Charlson Comorbidity Index, treatment facility type, clinical T or N status between the 2 groups. Tumor size ≥5 cm (odds ratio, 1.46; P = .006) was the only factor that predicted ICR use. Higher rates of T downstaging (39.7% vs 33.4%; P = .012), N downstaging (32.0% vs 23.4%; P < .001), and complete pathologic response (13.1% vs 5.9%; P < .001) occurred in ICR patients. Positive margins were seen more often in ICA patients (9.6% vs 5.5%; P = .001), but there was no difference in 5-year survival (ICR 35.9% vs ICA 37.2%; P = .33), and ICR was not associated with survival in multivariable analysis (hazard ratio = 1.04; P = .61). CONCLUSIONS: ICR for locally advanced distal esophageal adenocarcinoma is associated with a better local treatment effect, but not improved survival compared with ICA, which suggests that radiation can be used selectively in this clinical situation.
引用
- Liou DZ, Backhus LM, Lui NS, et al. Induction therapy for locally advanced distal esophageal adenocarcinoma: Is radiation Always necessary? J Thorac Cardiovasc Surg. 2018. PMID: 29530567. doi:10.1016/j.jtcvs.2017.12.136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。